These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 6683993

  • 1. Antitumor activity, induction of cross-resistance, and nephrotoxicity of a new platinum analogue, cis-1,1-diaminomethylcyclohexaneplatinum(II) sulfate, and of cis-diamminedichloroplatinum(II) in an immunocytoma model in the LOU/M rat.
    de Jong WH, Steerenberg PA, Vos JG, Bulten EJ, Verbeek F, Kruizinga W, Ruitenberg EJ.
    Cancer Res; 1983 Oct; 43(10):4927-34. PubMed ID: 6683993
    [Abstract] [Full Text] [Related]

  • 2. Synthesis and antitumor activity of a new cis-diammineplatinum (II) complex containing procaine hydrochloride.
    Cafaggi S, Esposito M, Parodi B, Vannozzi MO, Viale M, Pellecchia C, Fulco RA, Merlo F, Zicca A, Cadoni A.
    Anticancer Res; 1992 Oct; 12(6B):2285-92. PubMed ID: 1295476
    [Abstract] [Full Text] [Related]

  • 3. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 4. Resistance and cross-resistance of the IgM immunocytoma in the LOU/M Wsl rat for cisplatin, carboplatin, and iproplatin.
    Steerenberg PA, Vendrik CP, de Jong WH, de Groot G, Fichtinger-Schepman AM, Scheefhals AP, Schornagel JH.
    Cancer Chemother Pharmacol; 1988 Nov; 22(1):51-7. PubMed ID: 3293840
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C, Bettio F, Baccichetti F, Trevisan A, Giovagnini L, Fregona D.
    Chem Biol Interact; 2004 Jun 30; 148(1-2):37-48. PubMed ID: 15223355
    [Abstract] [Full Text] [Related]

  • 6. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
    Bodenner DL, Dedon PC, Keng PC, Katz JC, Borch RF.
    Cancer Res; 1986 Jun 30; 46(6):2751-5. PubMed ID: 3009000
    [Abstract] [Full Text] [Related]

  • 7. Ascorbato(1,2-diaminocyclohexane):platinum(II) complexes, a new series of water-soluble antitumor drugs.
    Hacker MP, Khokhar AR, Brown DB, McCormack JJ, Krakoff IH.
    Cancer Res; 1985 Oct 30; 45(10):4748-53. PubMed ID: 4040806
    [Abstract] [Full Text] [Related]

  • 8. New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells.
    Frühauf S, Zeller WJ.
    Cancer Res; 1991 Jun 01; 51(11):2943-8. PubMed ID: 2032232
    [Abstract] [Full Text] [Related]

  • 9. Antitumor, nephrotoxic and clastogenic effect of cis-DDP with DDTC or NAC.
    Konstantinov S, Topashka-Ancheva M, Karaivanova M, Zoneva G, Galova I.
    Neoplasma; 1994 Jun 01; 41(5):253-8. PubMed ID: 7854494
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs.
    Vendrik CP, de Jong WH, Van der Minnen AC, Fichtinger-Schepman AM, Steerenberg PA, Schornagel JH.
    Anticancer Res; 1990 Jun 01; 10(2A):447-52. PubMed ID: 2346318
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effect of para-aminobenzoic acid on the pharmacokinetics and urinary excretion of cis-diamminedichloroplatinum(II) in rats.
    Esposito M, Vannozzi M, Viale M, Pellecchia C, Civalleri D, Gogioso L.
    Anticancer Res; 1995 Jun 01; 15(6B):2541-7. PubMed ID: 8669820
    [Abstract] [Full Text] [Related]

  • 19. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
    Endo K, Akamatsu K, Matsumoto T, Morikawa K, Koizumi M, Mitsui H, Koizumi K.
    Anticancer Res; 1992 Jun 01; 12(1):49-58. PubMed ID: 1567181
    [Abstract] [Full Text] [Related]

  • 20. Increased therapeutic gain of combined cis-diamminedichloroplatinum (II) and whole body hyperthermia therapy by optimal heat/drug scheduling.
    Baba H, Siddik ZH, Strebel FR, Jenkins GN, Bull JM.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):7041-4. PubMed ID: 2582445
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.